sur B.R.A.I.N. Biotechnology Research And Information Network AG (ETR:DE000520)
BRAIN Biotech Secures Patent for CRISPR-BMC Technology
BRAIN Biotech, a leader in innovative biological solutions, announced the European Patent Office granted a patent for its CRISPR-BMC genome-editing technology. This novel CRISPR nuclease exhibits high activity across various organisms, opening significant commercial potential through licensing.
The BMC® technology enables precise genome editing in both prokaryotic and eukaryotic cells. BRAIN Biotech aims to optimize microbial production strains using this technology for producing biomolecules, enhancing manufacturing efficiency. The patent is valid in Europe, the UK, and Switzerland, with pending applications elsewhere.
CEO Adriaan Moelker highlighted the robust patent protection, emphasizing its applications in diverse fields, making manufacturing more cost-effective. R&D Head Alexander Pelzer noted the technology's speed and precision in developing production organisms. BRAIN Biotech plans to expand licensing activities further.
R. P.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de B.R.A.I.N. Biotechnology Research And Information Network AG